Proposed transaction will result in Biocon Biologics becoming a wholly-owned subsidiary of Biocon, simplifying the group ...

Indian biopharmaceutical company Biocon said on Saturday it would fully integrate its biosimilar unit Biocon Biologics as a wholly owned subsidiary, consolidating Biocon’s biosimilars and generics ...

As part of this announcement, Biocon's board has also approved raising funds to the tune of ₹4,500 crore through a Qualified ...

Biocon plans to merge Biocon Biologics, acquiring remaining stakes for $5.5 billion, enhancing its global biosimilars and ...

Indian pharmaceuticals firm Biocon Ltd. will buy out minority shareholders in Biocon Biologics Ltd. via a mix of cash and ...

Biocon has announced a bold step in the biopharmaceutical landscape by merging its biosimilars division, Biocon Biologics, ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. | Returning its stake in ...

The board of directors of Biocon are scheduled to meet on December 06, 2025, to consider and approve the proposals for ...

The deal is anticipated to be finalised in the first quarter of 2026, pending the fulfilment of all closing conditions.

When we created Biocon Biologics as a separate entity, the objective was clearly to attract investments and build global ...

Motilal Oswal is bullish on Biocon recommended buy rating on the stock with a target price of Rs 460 in its research report ...

Biocon will fully integrate its biosimilars arm, Biocon Biologics into the parent, in a deal valuing the unit at $5.5 billion ...